Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENGIC 02 - PRODIGE 86: modified FOLFIRINOX vs FOLFOX for small bowel adenocarcinoma
2023-505486-92-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Sep 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial of fluorouracil, oxaliplatin, irinotecan and levoleucovorin in small bowel adenocarcinoma (SBA) (2 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Progression at 8 months. Planned start Sep 2023; status: authorised.
02
Drugs
fluorouraciloxaliplatinirinotecanlevoleucovorin
03
Conditions
small bowel adenocarcinoma (SBA)
Beyond the preview
Go deeper on 2023-505486-92-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505486-92-00.